Gouynou, C., Pouillon, L., Rousseau, H., Zallot, C., Baumann, C., & Peyrin-Biroulet, L. (2018). Early changes in the pharmacokinetic profile of vedolizumab-treated patients with IBD may predict response after dose optimisation. Gut. https://doi.org/10.1136/gutjnl-2017-315766 (Original work published 2018)